Natco Pharma bags USFDA approval for Cabazitaxel Intravenous Solution; stock rises

25 Jul 2022 , 10:56 AM

The United States Food and Drug Administration has approved Natco Pharma Limited’s partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) in the 60mg/1.5mL (40mg/mL) strength.

Breckenridge and Natco are unable to comment further on the product’s launch date because it is confidential and cannot be disclosed at this time.

According to industry sales data, Jevtana Kit made $303 million in annual sales during the fiscal year ending May 2022.

Post this development, Natco Pharma was trading 0.11% higher at Rs654.95 against its previous close of Rs654.20 on NSE. It touched intraday high and low of Rs666 and Rs654 respectively.